D Durect Corp
D
Uždarymo kaina
0
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
Max
Darbuotojai | 13 |
|---|
Rekomendacijos | Neutralu |
|---|---|
12 mėnesių prognozė | +30.89% upside |
Rinkos kapitalizacija | 51M |
|---|---|
Ankstesnė atidarymo kaina | 0 |
Ankstesnė uždarymo kaina | 0 |
Durect Corp Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Durect Corp Prognozė
Kainos tikslas
By TipRanks
30.89% į viršų
12 mėnesių prognozė
Vidutinis 2.5 USD 30.89%
Aukščiausias 2.5 USD
Žemiausias 2.5 USD
Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Durect Corp kainas – Dist per pastaruosius 3 mėnesius.
Finansinės naujienos
$
Apie bendrovę Durect Corp
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
